Previous 10 | Next 10 |
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patient...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...
2024-04-22 09:39:43 ET More on Cidara Therapeutics Cidara receives $11M milestone payment from partner Mundipharma Cidara rallies 13% after hours on UK approval for Rezzayo Read the full article on Seeking Alpha For further details see: Cidara Therapeutic...
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patient...
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model - Late-breaking CBO421 data demonstrates improved efficacy compared to oleclumab...
2024-04-03 08:53:52 ET More on premarket gainers & stock Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects SELLAS Life Sciences GAAP EPS of -$1.3...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...
2024-02-12 14:26:19 ET More on Cidara Therapeutics Cidara rallies 13% after hours on UK approval for Rezzayo Cidara, Melinta announce publication of Rezzayo data in medical journal Seeking Alpha’s Quant Rating on Cidara Therapeutics Historical earnings...
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara’s Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...